We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Analysis

3rd Circ. Lipitor Ruling Smooths Way In Pay-For-Delay Suits

Law360, Fort Wayne (August 30, 2017, 5:57 PM EDT) -- The Third Circuit recently revived a suit accusing pharmaceutical companies of delaying generic competition for Lipitor and Effexor XR, a decision that will bolster drug buyers in pay-for-delay cases by beating down the specter of higher hurdles against bringing the suits.

In last week's decision, the appeals court said the buyers had adequately pled that Pfizer Inc. and Ranbaxy Laboratories Inc., in the Lipitor case, and Wyeth Inc. and Teva Pharmaceutical Industries Ltd., in the Effexor case, penned patent dispute settlement agreements that unlawfully delayed generic...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.